Gut Bacteria Treatment Shows Promise for Rare Genetic Kidney Condition
The Swedish biotech Oxthera reported positive preliminary Phase II results using its gut bacteria treatment,…
The potential of the microbiome to be used for the development of promising therapeutics and diagnostic approaches has spurred a hype around this emerging field. Over the last decade, researchers have found correlations between the human microbiome and a number of diseases, including inflammatory bowel disease, diabetes, autoimmune diseases, cancer, depression, and many more. As the number of clinical trials grows, investor interest is increasing.
Read on to find out more about the flourishing microbiome field and how it shows promise for the treatment of a large variety of diseases.
Beyond the Gut: An Atlas of the Human Microbiome
This report discusses the role of the gut and blood microbiomes in different diseases and how they can be used for biomarker discovery and for the development of therapeutics.
Go to ReportThe Swedish biotech Oxthera reported positive preliminary Phase II results using its gut bacteria treatment,…
UK-based Microbiotica has received a £4M investment from Seventure’s fund dedicated to investments in the…
The French biotech Enterome and Takeda are teaming up to fight Crohn’s disease, with a…
In recent years, our understanding of the human microbiome has reached an exciting momentum. It…
The microbes living on our skin can play an important role in skin conditions such…
Microsoft Genomics will work with Cambridge-based Eagle Genomics to scale up its artificial intelligence platform…
Update (27/09/2018): New investment from Dutch venture capital fund Innovation Industries brings A-Mansia's Series A…
Artist Alanna Lynch uses kombucha as an art medium to explore our relationship with the…
Dutch scientists have found that altering a patient’s microbiome with antibiotics before a vaccination can…
Summit Therapeutics obtained Phase II results showing its antibiotic for C. difficile infections was more…
With the rise of antimicrobial resistance across the globe, and with a dire lack of…
Netbiotix has raised €7.5M to bring its lead candidate for inflammatory bowel disease into clinical…